Sanofi India Limited (SANOFI) fair value: what the stock is really worth
As of Oct 1, 2026: fair value of Sanofi India Limited ₹2,214, price ₹3,037, upside -27.1%, quality 88 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Sanofi India Limited for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 1, 2026.
How to read this chart
60‑month range ₹2,415 – ₹7,083 · fair‑value band ₹1,650 – ₹2,798 · the ₹3,037 price screens above the ₹2,214 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Oct 1, 2026.
Follow Sanofi India in your weekly email
Every Wednesday you see whether Sanofi India is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Sanofi India Limited manufactures and trades in drugs and pharmaceutical products in India, Singapore and internationally.
Show more
Sanofi India Limited manufactures and trades in drugs and pharmaceutical products in India, Singapore and internationally. The company offers pharmaceutical products in various therapeutic areas, such as diabetes, cardiology, anti-infectives, and central nervous system under the Lantus, Toujeo, Soliqua, Clexane, Amaryl, Cardace, Lasix, Lasilactone, Glimepiride, Cetapin, Targocid, Frisium, Targocio, Combiflam, DePura, Allegra, Baralgan, BUSCOGAST, Dulcoflex, Enterogermina, Novalgin, and Avil brands through independent distributors. It also exports its products. The company was formerly known as Aventis Pharma Limited and changed its name to Sanofi India Limited in May 2012. The company was incorporated in 1956 and is headquartered in Mumbai, India. Sanofi India Limited operates as a subsidiary of Hoechst GmbH.
Stock analysis
Sanofi India Limited (SANOFI) currently trades at ₹3,037, while our model-based Fair Value estimate is ₹2,214, 27.1% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Multiples group reads highest at a median of ₹2,513 per share, and 3 of the 24 models we run sit above the ₹3,037 price.
Bear case: the Economic Profit group reads lowest at ₹756.49, and 21 of the 24 models stay below the price. Evidence for this calculation is high.
Scenario range: ₹1,650 (bear) to ₹2,798 (bull), the price of ₹3,037 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 88/100 (high quality), in the Healthcare sector.
Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.
Sanofi India Limited reported revenue of ₹18.4B in FY2025 versus ₹29.6B in FY2021, a compound −11.2%/yr. Reported net income was ₹3.3B in FY2025, compounding −23.3%/yr from FY2021.
Key figures
Market cap ₹69.9B (≈ $726M) · P/E ratio 21.6 · P/S ratio 3.84 · EPS (TTM) ₹140.68 · Dividend yield 1.6% · Net margin 17.8% · Return on equity 40.3% · Return on assets (EBIT) 43.5%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 50 out of 100 (low confidence).
What moves the price
The share trades about 35% below its 52-week high and at its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −1% fair-value upside, at −27%, SANOFI screens richer than that median.
Fair Value models
Bear ₹1,650Fair Value ₹2,214Bull ₹2,798
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then (₹69.83 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.40/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−8.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−12.8%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−8.7%
Start year 2020 (pandemic). Over 10 years: −1.8% a year
Revenue growth 21 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+4.5%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in INR ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in INR: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
−5.7%
Earnings growth per share plus dividend.
Earnings per share, growth per year−7.3%
Dividend (yield on the price)1.6%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−7.3% vs 0.7%, slowing
Profit margin 2004 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.30% → 25%
Start year 2020 (pandemic)
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+11.2%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (India: IMF forecast 4.1% a year to 2030, 4.7% from 2016 to 2025) that is about +6.7% a year for the price.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - General · 73 stocks
Beats the industry median on 9/13 measures
Overall it ranks above its industry peers.
Valuation
Quality Score88 · Top 25%
Fair Value upside−27.1% · Below median
Profitability
Return on equity (TTM)40.3% · Top 25%
Return on assets21.1% · Top 25%
Net margin (TTM)17.9% · Above median
Operating margin (TTM)24.3% · Above median
Growth and dividend
Revenue growth7.7% · Above median
Dividend yield (TTM)1.6% · Below median
Valuation Multiplesvs Drug Manufacturers - General median · lower = cheaper
P/E (TTM)21.6× · Cheaper than median
P/B9.34× · Priciest 25%
P/S (TTM)3.88× · Pricier than median
P/FCF16.5× · Cheaper than median
EV/EBITDA14.1× · Cheaper than median
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 21
FUTURE (revenue growth)39· sector 32
PAST (return on equity)100· sector 41
HEALTH (low debt)0· sector 92
DIVIDEND (yield)32· sector 41
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Sanofi India Limited Fair Value". https://www.fairvalue-calculator.com/stock/SANOFI
Frequently asked questions
Is Sanofi India Limited (SANOFI) overvalued or undervalued?
As of Oct 1, 2026, our model estimates a fair value of ₹2,214 versus a price of ₹3,037, about −27% upside (overvalued).
What is the fair value of SANOFI?
Our model-based fair value for Sanofi India Limited is ₹2,214 (as of Oct 1, 2026), built from audited fundamentals. The current price: ₹3,037.
What is the quality score of SANOFI?
Sanofi India Limited has a Quality Score of 88/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Sanofi India Limited (SANOFI)?
Our model-based price target is the fair value of ₹2,214 (as of Oct 1, 2026) from 24 valuation models. Cautious scenario ₹1,650, optimistic scenario ₹2,798. It is a calculation from audited fundamentals, not an analyst target.
What is the Sanofi India Limited stock forecast for 2026?
Our models put fair value at ₹2,214, about −27% upside versus a price of ₹3,037 (overvalued). Cautious scenario ₹1,650, optimistic scenario ₹2,798. The calculation is refreshed regularly with new filings.
What is the revenue of Sanofi India Limited (SANOFI)?
Sanofi India Limited reported trailing-twelve-month revenue of about ₹18.1B (latest available figure, as of Oct 1, 2026).
Does Sanofi India Limited pay a dividend?
Sanofi India Limited currently shows a dividend yield of about 1.58% relative to its recent price (as of Oct 1, 2026).
What growth is priced into Sanofi India Limited (SANOFI)?
For today's price to be fair in a discounted-cash-flow model, Sanofi India Limited would have to grow free cash flow by +11.2 % per year for five years (discount rate 12.4 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew -8.7 % per year. As of Oct 1, 2026.
What discount rate (WACC) does the fair value of SANOFI use?
Our models discount Sanofi India Limited at 12.4 %: a base by market capitalisation (small), damped by beta 0.19, country premium for India. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Sanofi India Limited that is +11.2 % per year a year over ten years, using the same discount rate (12.4 %) and the same formula as our fair value.
How much growth has Sanofi India Limited (SANOFI) delivered so far?
Over the past 5 years revenue at Sanofi India Limited grew -8.7 % a year. The price currently implies +11.2 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Sanofi India Limited (SANOFI) growing?
The median revenue growth in the sector is +4.7 % a year. That is the yardstick for the growth priced into Sanofi India Limited (+11.2 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Sanofi India Limited (SANOFI)?
The free-cash-flow yield on the price is 6.08 %: that much free cash flow Sanofi India Limited produces per unit of market value. When it exceeds the discount rate of our models (12.4 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Sanofi India Limited (SANOFI)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Sanofi India Limited it is ₹2,214 per share (as of Oct 1, 2026), against a price of ₹3,037. It is the blended result of 24 valuation models (cash flow, earnings, asset, dividend).
Is Sanofi India Limited stock overvalued or undervalued in 2026?
As of Oct 1, 2026, SANOFI trades above its calculated fair value: price ₹3,037, fair value ₹2,214, a gap of about −27% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of SANOFI?
No. The price is what the market pays today (₹3,037); the fair value is what the company's own numbers justify (₹2,214). For Sanofi India Limited the two are ₹823.08 per share apart. That gap is exactly why we show both numbers side by side.
How much is Sanofi India Limited worth?
The market values Sanofi India Limited at about ₹69.9B (market capitalisation, as of Oct 1, 2026). Per share that is ₹3,037; our models calculate a fair value of ₹2,214 per share.
What do the bullish and bearish scenarios say about SANOFI?
Our models span a range for Sanofi India Limited: cautious scenario ₹1,650, base ₹2,214, optimistic ₹2,798 per share (as of Oct 1, 2026, price ₹3,037). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of SANOFI?
Sanofi India Limited trades at a price-to-earnings ratio of 21.6 (as of Oct 1, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ₹2,214 is built from several models across several years. Other multiples: P/B 9.3, P/S 3.9, EV/EBITDA 14.1.
How solid is the balance sheet of Sanofi India Limited (SANOFI)?
Balance-sheet figures for Sanofi India Limited (as of Oct 1, 2026): return on equity 40.3%. They feed the Quality Score of 88/100, which measures business quality independently of the share price.
How far is SANOFI from its 52-week high?
Sanofi India Limited trades at ₹3,037, about 35% below its 52-week high of ₹4,668 and at the low of ₹3,037 (as of Oct 1, 2026). Distance from the high says nothing about value: that is what the fair value of ₹2,214 is for.
Which stocks are comparable to Sanofi India Limited?
From the same area (Healthcare) we also value Eli Lilly and Company, Johnson & Johnson,, AbbVie Inc, Roche Holding, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Sanofi India Limited stock attractive at the current price?
The data as of Oct 1, 2026: price ₹3,037, calculated fair value ₹2,214 (−27%), Quality Score 88/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of SANOFI calculated?
We run Sanofi India Limited through 24 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ₹2,214, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Sanofi India Limited itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Sanofi India Limited (SANOFI)?
The closing price on Oct 1, 2026 was ₹3,037. Our model-based fair value is ₹2,214, about −27% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Sanofi India Limited right now?
A high-quality business (quality 88/100), yet the market already pays well above fair value. Quality at a full price, with little margin of safety. The price sits above even our optimistic bull case (₹2,798). The favourable scenario is already priced in.
Where does the earnings growth of Sanofi India Limited (SANOFI) come from?
Earnings per share at Sanofi India Limited grew +4.7 % a year from 2014 to 2025. Broken into its drivers: revenue per share −1.2 %, EBIT margin −0.5 %, tax rate +1.6 %, residual (interest, one-offs) +4.8 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of Sanofi India Limited
How large is the market capitalisation of Sanofi India Limited (SANOFI)?
The market capitalisation of Sanofi India Limited is ₹69.9B (≈ $726M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Sanofi India Limited (SANOFI)?
The price-to-sales ratio of Sanofi India Limited is 3.84 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Sanofi India Limited (SANOFI)?
Earnings per share at Sanofi India Limited are ₹140.68 (price ÷ EPS = P/E 21.6). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Sanofi India Limited (SANOFI)?
The dividend yield of Sanofi India Limited is 1.6% (payout 34.1%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Sanofi India Limited (SANOFI)?
The net margin of Sanofi India Limited is 17.8% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Sanofi India Limited (SANOFI)?
The return on equity (ROE) of Sanofi India Limited is 40.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Sanofi India Limited (SANOFI)?
On an EBIT basis the return on assets of Sanofi India Limited is 43.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Sanofi India Limited (SANOFI)?
The operating margin of Sanofi India Limited is 24.3% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Sanofi India Limited (SANOFI)?
Revenue at Sanofi India Limited is growing +7.7% versus a year earlier (3y avg −12.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Sanofi India Limited (SANOFI)?
Earnings per share at Sanofi India Limited are growing +20.1% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does Sanofi India Limited (SANOFI) hold?
Sanofi India Limited holds more cash than debt, ₹2.6B net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Sanofi India Limited in the live analysis
One click puts Sanofi India Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
